

DIAGNOSIS AND PREVENTION OF INFECTION BY PHLEBOTOMUS FEVER GROUP VIRUSES

ANNUAL REPORT

DAVID H.L. BISHOP FEBRUARY 3, 1989

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-87-C-7069

Institute of Virology Mansfield Road, Oxford OX1 3SR, UK

Approved for public release; distribution unlimited




Findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents

REPORT	N PAGE			rm Approved MB No. 0704-0188		
1a. REPORT SECURITY CLASSIFICATION		1b. RESTRICTIVE MARKINGS				
Unclassified		<u> </u>				
2a. SECURITY CLASSIFICATION AUTHORITY		3. DISTRIBUTION / AVAILABILITY OF REPORT				
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE		Approved for public release; distribution unlimited				
4. PERFORMING ORGANIZATION REPORT NUMBER(S)		5. MONITORING ORGANIZATION REPORT NUMBER(S)				
6a. NAME OF PERFORMING ORGANIZATION	6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MO	ONITORING ORGAN	IZATION		
Institute of Virology	(ii appiicable)					
6c. ADDRESS (City, State, and ZIP Code)		7b. ADDRESS (City, State, and ZIP Code)				
Mansfield Road						
Oxford OX1 3SR, UK						
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER					
ORGANIZATION U.S. Army Medical (If applicable) Research & Development Command		DAMD17-87-c-7069				
8c. ADDRESS (City, State, and ZIP Code)		10. SOURCE OF FUNDING NUMBERS				
Fort Detrick Frederick, Maryland 21701-5012		PROGRAM ELEMENT NO.	PROJECT NO. 3M1-	TASK NO.	WORK UNIT ACCESSION NO.	
		62770A	62770A871	AB	357	
11. TITLE (Include Security Classification)						
(U) Diagnosis and Prevention of	f Infection by P	hlebotomus F	ever Group V	liruses		
12. PERSONAL AUTHOR(S)						
David H.L. Bishop 13a. TYPE OF REPORT 13b. TIME CO	OVERED	14. DATE OF REPO	RT (Year, Month, C	Day) 15. PAG	E COUNT	
Annual FROM 2/						
16. SUPPLEMENTARY NOTATION						
		_	_			
17. COSATI CODES	Continue on reverse if necessary and identify by block number)					
FIELD GROUP SUB-GROUP 06 13	· · · · · · · · · · · · · · · · · · ·	ebovirus; Rift Valley Fever;				
06 03						
19. ALSTRACT (Continue on reverse if necessary	and identify by block n	umber)				
Punta toro M and S and cDNA pro	obes for hybridi	zation to vi	rus infected	d cells ha	ive been	
produced in plasmids that can l						
specifically with PT virus info						
yield (10-40% total cellular p Valley fever virus mutant M 12						
the M cDNA has been sequenced.						
comparison with RVFV ZZ 501.						
obtained.						
	=	Tali - 100-100				
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT UNCLASSIFIED/UNLIMITED SAME AS R	21 ABSTRACT SECURITY CLASSIFICATION Unclassified					
22a. NAME OF RESPONSIBLE INDIVIDUAL	225 TELEPHONE (22b. TELEPHONE (Include Area Code) 22c. OFFICE SYMBOL				
Mary Frances Bostian	301-663-7325 SGRD-RMI-S					

TABLE OF CONTENTS

I.	SUI	MMARY	2	
п.	REPORT			
	A.	Introduction	2	
	B.	Results from this Reporting Period	4	
	C.	Summary of Progress Report	5	
	D.	Literature Cited	6	
Distribution List				



I. SUMMARY

The objectives of the contract are to develop new diagnostic procedures and new vaccine strategies pertinent to selected Phlebotomus fever (PHL) group viruses, viruses that constitute the *Phlebovirus* genus of the negative-sense RNA virus family Bunyaviridae. [Bishop et al., 1980]. This genus of viruses includes members that are known animal [including human] pathogens and that are therefore of consequence to military and civilian personnel in particular regions of the world [Bishop & Shope, 1979].

The development of new diagnostic tools for the specific identification of PHL group viruses is being investigated using eukaryotic expression vectors and cDNA clones of particular phlebovirus genes that are being prepared or that are available to us. Two expression systems are under study, vaccinia and the insect specific baculovirus expression vectors. So far, it has proven difficult to express the complete M RNA gene products of Punta Toro (PT) phlebovirus using either vector. Recombinant vaccinia viruses have, however, been made that express part of the PT M RNA, producing the PT glycoproteins G1 and G2 [Matsuoka et al., 1988]. The expressed products have been characterized. The expression of PT S RNA gene products [Overton et al., 1987] using Autographa californica nuclear polyhedrosis virus [AcNPV] baculovirus vectors also been reported.

The objective of developing new vaccine strategies for PHL group viruses is being realized through the characterization of an attenuated, candidate vaccine derivative of Rift valley fever [RVF] phlebovirus [the M12 mutant of RVFV isolate ZZ548]. This candidate vaccine was previously developed by staff of the Principal Investigator working at USAMRIID [Caplen et al., 1984]. The complete sequence of the viral M RNA of the M12 RVFV derivative has been obtained [Takehara et al., 1989]. The M RNA of the RVFV M12 derivative has been expressed in baculovirus vectors and the products characterized [Takehara et al., manuscript in preparation].

II. REPORT

A. Introduction

Our analyses have been directed towards developing new strategies for the development of phlebovirus vaccines and diagnostic reagents. Initial studies, supported by prior U.S. Army Medical Research and Development contracts, were aimed at characterising the genome and structural components of phleboviruses.

With the demonstration of a tripartite RNA genome for phleboviruses, genetic analyses were then undertaken to delineate the coding strategies of the viral RNA species and to determine if recombinant viruses could be obtained and used for vaccine purposes. By analyses of intertypic reassortant PT viruses we initially showed that the viral 7x10⁵ dalton small [S] RNA species codes for the viral 26.9x10³ dalton nucleocapsid [N] protein. The results of cloning and sequencing the S RNA of PT phlebovirus [Ihara et al., 1984] confirmed these data and showed that an open reading frame in the viral-complementary S RNA sequence coded for N [S mRNA]. A second open reading frame in the viral-sense strand, coding for a 29.1x10³ dalton non-structural protein, NS_S [Ihara et al., 1984], was also identified. The two subgenomic PT S induced mRNA species [one viral-complementary, the other viral-sense] were characterized with regard to their 3' and 5' end sequences and rates of synthesis in infected cells [Ihara et al., 1985a; Emery & Bishop, 1987].

The results of cloning and sequencing the 2x106 dalton middle [M] size RNA of PT virus [Ihara et al., 1985b] demonstrated that the PT M RNA codes for the 50-70x10³ dalton viral glycoproteins, G1 and G2. A 30x10³ dalton non-structural protein, NS_M, that constitutes the amino terminal end of the PT glycoprotein precursor was also identified. The data showed that the order of the PT M gene products was NS_M-G1-G2. The PT M viral-complementary mRNA species were characterized [Ihara et al., 1985a]. The results obtained for the PT M RNA correlated with the data reported by Collett and associates [1985] for RVFV M RNA and its gene products [RVFV M gene order: NS_M-G2-G1]. Although not proven, it is assumed that the phlebovirus 3x10⁶ dalton large [L] RNA species codes for the 200x10³ dalton large protein [a putative transcriptase component] found in viruses.

The genetic studies, including interference assays, reported from the work conducted in the previous contract, indicated that although intertypic reassortant viruses could be obtained, heterotypic virus interactions were not demonstrable (i.e., heterotypic phleboviruses did not interfere with each other and did not reassort their genomes in dual virus infections). Although not all phleboviruses were tested for genetic interactions, the results did not hold out much hope for this approach for vaccine development. Consequently, an alternative approach, that of developing candidate, including subunit, vaccines is under investigation in this contract. These objectives, together with research directed towards the development of new and specific diagnostic reagents for phleboviruses form the principal objectives of this contract.

B. Results from this Reporting Period.

Expression of the MRNA of the M12 candidate vaccine of RVFV using baculovirus vectors

The sequence of the M RNA of the ZZ501 strain of RVFV has been reported by Collett and associates (1985). In order to characterize the candidate RVFV vaccine that was produced from the related ZZ548 RVFV [Caplen et al., 1984], we sequenced the M RNA of the M12 derivative [Takehara et al., 1989]. The sequence was obtained by analyses of λ cDNA clones. The RVFV M12 M RNA was thereby deduced to be 3885 nucleotides long (mol. wt. 1.38x106) coding, in its viral-complementary sequence, for a single long gene product [the viral glycoprotein precursor] that is comprised of 1197 amino acids (130,000 daltons). The gene product is initiated by a methionine (AUG) codon at the M RNA nucleotide residues 21-23.

Unlike the RNA of the parent ZZ548 virus or that of ZZ501, there is a second AUG codon [residues 9-11] in the viral-complementary sequence upstream of the M12 M gene product. It is followed by valine and histidine codons, then a translation terminator [TAA, residues 18-20]. Of interest therefore to the question of why the M12 mutant is attenuated is whether the presence of this upstream short open reading frame (ORF) inhibits or reduces the expression of the viral glycoprotein. For this reason the M12 cDNA has been inserted into baculovirus transfer vector, pAcYM1 (Matsuura et al., 1987). A variety of cDNA constructions have been made (e.g., with or without the upstream ORF) and recombinant baculoviruses prepared. Four recombinant baculoviruses have been analysed. The M1 baculovirus has both the upstream ORF and the ORF coding for the M glycoprotein precursor. The M2 baculovirus lacks the upstream ORF but contains the entire coding region of the glycoprotein precursor. The M3 recombinant lacks the upstream ORF and the sequences coding for the NS,, gene product. The M4 recombinant lacks the upstream ORF and the sequences coding for the RVFV G1 gene product.

In order to characterize the RVFV proteins that are expressed, the recombinant baculoviruses have been analysed by Western and immunofluorescence analyses using G1 and G2 specific monoclonal antibodies provided to us by Dr Jonathan Smith of USAMRIID. The studies have shown that the RVFV G1 and G2 proteins are made by all the recombinants (except in the case of M4). The glycoproteins are processed into the expected size classes and

appear on the surface of the baculovirus infected cells, although whether these are intrinsic properties of the proteins or related to the course of the baculovirus infection, are not known. From the pattern of surface expression, as analysed by the monoclonal antibodies, it appears that the G2 protein is present all over the cell surface while the G1 protein is segregated into discrete entities. The data show that there is little, if any, difference in the level of expression of the RVFV glycoproteins whether the upstream ORF is present or absent.

Analyses of the phenotypes of the expressed RVFV glycoproteins have shown that they mediate cell fusion at acid pH values. The cell fusion was inhibited by pretreatment with the G1 monoclonal antibody but not after pretreatment with the G2 monoclonal antibody.

The data on the expression of the RVFV M clones is in the process of preparation for publication.

Identification of RVFV S cDNA clones

From the cDNA library that yielded the M cDNA clones, phage containing RVFV S cDNA sequences have been sought. The library appears to contain 95% recombinant phage (based on the recovery of phage and the frequency of M specific clones). Consequently it was considered likely that there should also be S-specific clones in the library. DNA preparations from non-M phage were therefore sought and recovered by their ability to hybridize to RVFV RNA in "Northern" analyses. This procedure identified RVFV S cDNA clones. Several cDNA clones were obtained and the sizes of their inserts determined by restriction analyses of the DNA. The largest DNA inserts have been sequenced. The sequence obtained for approximately 800 nucleotides of S cDNA predict a protein that is comparable to the NS_S protein of PT and Sicilian sandfly fever phleboviruses. Studies are continuing to find cDNA clones representing the rest of the RVFV S RNA.

C. Summary of Progress Report

The sequence of the M RNA of the M12 derivative of RVFV ZZ548 has been inserted into baculovirus expression vectors and the properties of the expressed products have been investigated. The glycoproteins are processed and

transported to the infected cell surface. Cell fusion at acid pH values has been documented. cDNA clones representing part of the S RNA of RVFV ZZ548 have been obtained and their sequences determined.

D Literature Cited.

- Bishop, D.H.L., Calisher, C., Casals, J., Chumakov, M.P., Gaidomovich, S.Ya., Hannoun, C., Lvov, D.K., Marshall, I.D., Oker-Blom, N., Pettersson, R.F., Porterfield, J.S., Russell, P.K., Shope, R.E., and Westaway, E.G., 1980, Bunyaviridae. *Intervirology* 14:125-143.
- Bishop, D.H.L., and Shope, R.E., 1979, Bunyaviridae, <u>In</u> Comprehensive Virology, Volume 14, (ed. FH. Fraenkel-Conrat and R.R. Wagner), pp.1-156. Plenum Press, New York.
- Caplen, H., Peters, C.J. and Bishop, D.H.L. 1985. Mutagen directed attenuation of Rift Valley fever virus as a method for vaccine development. *Journal of General Virology*, 66:2271-2277.
- Collett, M.S., Purchio, A.F., Keegan, K., Frazier, S., Hays, W., Anderson, D.K., Parker, M.D., Schmaljohn, JC., Schmidt, J., and Dalrymple, J.M. 1985, Complete nucleotide sequence of the M RNA segment of Rift valley fever virus. Virology 114:228-245.
- 1.Emery, V.C., and Bishop, D.H.L. 1987, The development of multiple expression vectors for high level synthesis of eukaryotic proteins: expression of LCMV N and AcNPV polyhedrin protein by a recombinant baculovirus. Protein Engineering 1:359-366.
- Ihara, T., Akashi, H., and Bishop, D.H.L., 1984, Novel coding strategy (ambisense genomic RNA) revealed by sequence analyses of Punta Toro phlebovirus S RNA. Virology 136:293-306.
- Ihara, T., Matsuura, Y., and Bishop, D.H.L. 1985a. Analyses of the mRNA transcription processes of Punta Toro phlebovirus (Bunyaviridae). *Virology* 147:317-325.
- Ihara, T., Smith, J., Dalrymple, J.M., and Bishop, D.H.L. 1985b. Complete sequences of the glycoprotein and M RNA of Punta Toro phlebovirus compared to those of Rift Valley fever virus. Virology 144:246-259.

- 2.Matsuoka, Y., Ihara, T., Bishop, D.H.L. and Compans, R.W. 1988. Intracellular accumulation of Punta Toro virus glycoprotein expressed from cloned cDNA. Virology, 167:251-260.
- 3.Matsuura, Y., Possee, R.D., Overton, H.A., and Bishop, D.H.L. 1987. Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. *Journal of General Virology*, 68:1233-1250.
- 4.Overton, H.A., Ihara, T., and Bishop, D.H.L. 1987. Identification of the N and NS_S proteins coded by the ambisense S RNA of Punta Toro phlebovirus using monospecific antisera raised to baculovirus expressed N and NS_S proteins. Virology, 157:338-350.
- 5.Takehara, K., Min, M-K., Sugiyama, K., Battles, J., Emery, V.C., Dalrymple, J.M., and Bishop, D.H.L. 1989. Identification of mutations in the M RNA of a candidate vaccine strain of Rift valley fever virus. Virology, in press.

References 1-5 came from work supported by this contract.

3

DISTRIBUTION LIST

Commander 5 copies

U.S. Army Medical Research Institute of Infectious Diseases
ATTN: SGRD-UIZ-M
Fort Detrick, Frederick, MD 21701-5011

1 copy

Commander US Army Medical Research & Development

Command ATTN: SGRD-RMI-S Fort Detrick, Frederick, MD 21701-5012

Defense Technical Information Center (DTIC) ATTN: DTIC-DDA 2 copies

Cameron Station Alexandria, VA 22314

1 copy

School of Medicine
Uniformed Services University of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20014

1 сору

Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM

Fort Sam Houston, TX 78234